Nutrichem(BJ:833819) Xin Lang Cai Jing·2025-10-31 05:08Core Viewpoint - YingTai Bio is a leading company in the domestic pesticide industry, focusing on the research, production, and sales of pesticide active ingredients and formulations, with a strong market presence and first-mover advantage in overseas market registrations [1] Group 1: Business Performance - In Q3 2025, YingTai Bio achieved a revenue of 4.434 billion yuan, ranking 9th in the industry, surpassing the industry average of 3.784 billion yuan and the median of 2.036 billion yuan, but significantly behind the top competitors [2] - The net profit for the same period was -11.6313 million yuan, ranking 26th in the industry, well below the industry average of 171 million yuan and the median of 95.2356 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, YingTai Bio's debt-to-asset ratio was 56.10%, slightly down from 56.45% year-on-year, but still above the industry average of 46.06%, indicating relatively high debt pressure [3] - The gross profit margin for Q3 2025 was 12.38%, an increase from 11.44% year-on-year, but still below the industry average of 21.70%, suggesting a need for improved profitability [3] Group 3: Management Compensation - The chairman, Chen Boyang, received a salary of 1.3463 million yuan in 2024, a decrease of 288,700 yuan from 2023 [4] - The general manager, Liu Xiaoliang, earned 729,000 yuan in 2024, down 165,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.74% to 23,600, while the average number of shares held per shareholder increased by 6.09% to 51,300 [5] - The company is expected to benefit from a partial recovery in the agricultural chemical industry, leveraging its market channels and first-mover advantages [5] Group 5: Future Outlook - Analysts project YingTai Bio's net profit for 2025 to be 42 million yuan, increasing to 153 million yuan in 2026 and 268 million yuan in 2027, maintaining a "buy" rating [5] - Another analysis indicates a reduction in profit forecasts for 2025 to 23 million yuan, 181 million yuan in 2026, and 322 million yuan in 2027, also maintaining a "buy" rating [6]